Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors. This evidence concerns the gene PLK1 and chronic myelogenous leukemia, BCR-ABL1 positive.